BioSpace News Archive

Redbud Labs (“Redbud”) continued to expand in 2019, adding new resources in engineering and manufacturing

Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today announced it has appointed industry healthcare veteran and leader Rebecca J. Fischer to its Board of Directors.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

N.W. Fulcher Limited (“Fulcher”) announces that it has acquired ownership of unsecured convertible debentures in the aggregate principal amount of $1,000,000 (the “Debentures”) of Nova Leap Health Corp. (TSXV: NLH) (“Nova Leap”), with its head office at 5003-7071 Bayers Road, Halifax, Nova Scotia, B3L 2C2.

Pharming Group N.V. (Euronext Amsterdam: PHARM) today announced it has entered into a definitive agreement with Swedish Orphan Biovitrum AB (publ) (“Sobi”) to reacquire the commercial rights to Pharming’s product, RUCONEST®, in all remaining territories, which includes all remaining EU markets

The primary endpoint is the incidence and severity of treatment-emergent adverse events, key secondary endpoints are objective response rate and PET-negative complete response rate at the end of treatment.

Co-founder of Brisbane-based gut analysis company Microba, Professor Phil Hugenholtz, has been announced as the next Vice President of the International Society for Microbial Ecology (ISME).

This open-label, multi-center Phase 2a clinical trial will assess the safety and efficacy of MILs alone and in combination with nivolumab.

CVS Health Corporation (NYSE: CVS) today announced that Larry Merlo, President and Chief Executive Officer, Eva Boratto, Executive Vice President and Chief Financial Officer, and Karen Lynch, Executive Vice President and President of Aetna will be speaking to investors at the J.P. Morgan Healthcare Conference

MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tafasitamab, an anti-CD19 antibody, for the treatment of relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL).